Nexalin Technology, Inc.
NXLHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeNexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. With a market capitalization of $4.0M, it sits in micro-cap territory. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia.
Market Cap
$4.0M
Beta
3.98
P/E (TTM)
—
P/E (Fwd)
-0.52
EPS (TTM)
$-13.85
EPS (Fwd)
$-9.30
ROE
-240.3%
ROA
-119.2%
Cash
$1.0M
Total Debt
$0
Free CF
-$2.5M
52W Change
-79.3%
Annual Financials
Cash vs Debt
Where NXL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NXL finished 1046.30% above its 150-day moving average ($0.54) and 914.75% above its 200-day moving average ($0.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NXL overbought or oversold?
At the September 3, 2026 close, NXL's RSI(14) was 85.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nexalin Technology, Inc. reports $1.0M in cash and $0 in total debt. Free cash flow is running at -$2.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -240.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.3M to $302K.
A beta of 3.98 means NXL is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nexalin Technology, Inc.'s trajectory.